Sign in
Active, not recruitingNo phase

Microfluidic Assessment of Clinical Outcomes in Preterm Newborns

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Active, not recruiting
People taking part
293 people enrolled
Started
14 Nov 2017
Expected to end
31 Dec 2026
Type of study
Observational, 3 groups
Treatments tested
  • Blood Collection Preterm
  • Blood Collection Term
  • Adult Blood collection
Record updated
13 February 2026

Who can take part

Age
23 weeks to 42 weeks
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 5 criteriaShow less

Who can take part

  • For preterm neonates <32 weeks gestation at birth with no known or suspected congenital anomalies
  • For term neonates >36 weeks gestation at birth with no known or suspected congenital anomalies

Who cannot take part

  • Congenital defects, suspected genetic disorders, 32-36 weeks completed gestation, or lack of consent; Healthy Adult:
  • Exclusion Criteria Taking any immune modifying medications or have an active immune modifying disease process
  • Inclusion criteria Between the ages of 18 and 65 years of age

Where in United States

  • UF HealthGainesville, United States

About the trial

What the trial wants to find out

Sepsis has its greatest impact in the prematurely born (preterm) population. Neonatal sepsis (sepsis within the first month of life) causes over one million deaths worldwide annually, and is one of the most common, difficult and costly problems to diagnose, treat and prevent. The preterm infant can suffer rates of sepsis up to 1000-fold higher than the full-term infant, and bears the brunt of the associated mortality and lifelong sepsis-survivor morbidity.

Read full original descriptionShow less

The project is enabled by several novel, validated, microfluidic technologies that are robust and easy to use with little training. These technologies provide comprehensive measures of the functionality of blood PMN population; a critical cellular component of innate immunity. The study team will also extract high-quality nucleic acids from microfluidic-sorted PMNs for transcriptomic analyses. Collectively, these techniques require a total of 250 microliters (µL) of blood, which makes them particularly useful for preterm infants where sample volume is limited, and facilitates serial assessments with unprecedented temporal resolution of key functions of PMNs.

These studies, integrated with bioinformatics approaches, will generate new tools for diagnosing sepsis in the newborn and predicting clinical outcomes. Such approaches have the capability to dramatically change the clinical management of the preterm infant, and potentially improve long-term outcomes while reducing hospital costs.

The 3 groups in the trial

  • Preterm Neonates

    Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.

    Treatment: Blood Collection Preterm

  • Term Neonates

    Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.

    Treatment: Blood Collection Term

  • Healthy Adult

    One-time whole blood draw of 1ml collection

    Treatment: Adult Blood collection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 February 2026